Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Almirall Knocked Back By US Woes, Could Affect Other Companies Too

Executive Summary

Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.

You may also be interested in...



Interview: Almirall CEO Guenter Plots 'Play To Win' Future

Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.

Almirall To Put More Skin In The Game With Derma Buys

The Spanish company has a lot riding on tildrakizumab, the psoriasis drug licensed from Sun Pharma which could get the green light in Europe before year-end. Until then, Almirall is scouring the market for bolt-on deals.

Guenter Stays Focused After Almirall's Annus Horribilis

Peter Guenter, brought in from Sanofi to fix the problems at Almirall, is staying focused on 2018 as he outlines his plan to rebuild the Spanish company. Almirall will continue reallocating resources and seeking bolt-on deals to establish a sustainable dermatology business as it rolls out Skilarence and tildrakizumab in Europe.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel